| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:c-Met/HDAC-IN-3
CAS:2439175-23-0
Package:25mg/RMB 15000;100mg/RMB 25500;50mg/RMB 19800
|
3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[4-[[7-[[7-(hydroxyamino)-7-oxoheptyl]oxy]-6-methoxy-4-quinolinyl]oxy]phenyl]-2-oxo- manufacturers
- c-Met/HDAC-IN-3
-
- $2120.00 / 25mg
-
2025-10-27
- CAS:2439175-23-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[4-[[7-[[7-(hydroxyamino)-7-oxoheptyl]oxy]-6-methoxy-4-quinolinyl]oxy]phenyl]-2-oxo- Basic information |
| | 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[4-[[7-[[7-(hydroxyamino)-7-oxoheptyl]oxy]-6-methoxy-4-quinolinyl]oxy]phenyl]-2-oxo- Chemical Properties |
| density | 1.337±0.06 g/cm3(Predicted) | | pka | 8.51±0.20(Predicted) |
| | 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[4-[[7-[[7-(hydroxyamino)-7-oxoheptyl]oxy]-6-methoxy-4-quinolinyl]oxy]phenyl]-2-oxo- Usage And Synthesis |
| Uses | c-Met/HDAC-IN-3 (Compound 15f) is a dual c-Met and HDAC inhibitor with IC50 values of 12.50 nM and 26.97 nM against c-Met and HDAC1, respectively. c-Met/HDAC-IN-3 induces apoptosis and cause cell cycle arrest in G2/M phase[1]. | | IC 50 | HDAC1: 26.97 nM (IC50) | | References | [1] Hu H, et al. Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy. Bioorg Chem. 2020 Aug;101:103970. DOI:10.1016/j.bioorg.2020.103970 |
| | 3-Pyrrolidinecarboxamide, 1-(4-fluorophenyl)-N-[4-[[7-[[7-(hydroxyamino)-7-oxoheptyl]oxy]-6-methoxy-4-quinolinyl]oxy]phenyl]-2-oxo- Preparation Products And Raw materials |
|